CTOs on the Move


 
InnovoTex Inc. is a mid-stage pharmaceutical company developing the TEX Core portfolio of novel therapeutics capable of targeting multiple solid tumor indications.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Pharmessen Scientific

Pharmessen Scientific is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innovation

Innovation is the leading provider of Pharmacy Intelligence™ and pharmacy automation to the retail, hospital, government, and mail order pharmacy markets. Our PharmASSIST® suite of pharmacy automation and process optimization solutions enable all types of pharmacies to increase operational efficiency, enhance patient safety, and provide a higher quality of patient care. Leveraging our unparalleled Pharmacy Intelligence, you can optimize your pharmacy fulfillment process, develop a proven ROI, and gain complete confidence in your automation decisions before investing. Innovation is a name we carry proudly. It is what we do and in many ways who we are. For three and a half decades we have been bringing new technology to industry. Our approach is simple. We start by understanding the problem and then apply all of our talent, expertise, and resources to create new and inventive ways to solve them. That is Innovation.

Genesys Venture

Genesys Venture Inc. is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Boehringer Ingelheim Pharma

Boehringer Ingelheim Pharma Inc. is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SAB Biotherapeutics

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.